CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 6.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 945,267 shares of the company’s stock after selling 60,946 shares during the period. Loomis Sayles & Co. L P’s holdings in CRISPR Therapeutics were worth $44,408,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. Global Trust Asset Management LLC lifted its stake in CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC grew its holdings in shares of CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after purchasing an additional 307 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics during the second quarter worth about $35,000. Finally, Denver PWM LLC purchased a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at approximately $45,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on CRSP shares. Truist Financial reduced their target price on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They set a “buy” rating and a $90.00 target price for the company. Barclays reduced their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $74.94.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $50.40 on Tuesday. CRISPR Therapeutics AG has a 1-year low of $43.42 and a 1-year high of $91.10. The stock has a market cap of $4.30 billion, a P/E ratio of -17.81 and a beta of 1.67. The firm has a fifty day moving average price of $47.98 and a 200 day moving average price of $51.73.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the prior year, the firm earned ($1.41) earnings per share. Sell-side analysts expect that CRISPR Therapeutics AG will post -5.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. The trade was a 13.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,382 shares of company stock valued at $1,917,679. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.